Back to Browse Journals » Clinical Pharmacology: Advances and Applications » Volume 2

Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine

Authors Vincenzo Barrese, Francesco Miceli, Maria Virginia Soldovieri, et al

Published Date December 2010 Volume 2010:2 Pages 225—236

DOI http://dx.doi.org/10.2147/CPAA.S15369

Published 7 December 2010

Vincenzo Barrese1, Francesco Miceli2, Maria Virginia Soldovieri3, Paolo Ambrosino3, Fabio Arturo Iannotti3, Maria Roberta Cilio2, Maurizio Taglialatela1,3
1Department of Neuroscience, University of Naples Federico II, Naples; 2Division of Neurology, IRCCS Bambino Gesù Children's Hospital, Rome; 3Department of Health Science, University of Molise, Campobasso, Italy

Abstract: Despite the availability of over 20 antiepileptic drugs, about 30% of epileptic patients do not achieve seizure control. Thus, identification of additional molecules targeting novel molecular mechanisms is a primary effort in today's antiepileptic drug research. This paper reviews the pharmacological development of retigabine, an antiepileptic drug with a novel mechanism of action, namely the activation of voltage-gated potassium channels of the Kv7 subfamily. These channels, which act as widespread regulators of intrinsic neuronal excitability and of neurotransmitter-induced network excitability changes, are currently viewed among the most promising targets for anticonvulsant pharmacotherapy. In particular, the present work reviews the pathophysiological role of Kv7 channels in neuronal function, the molecular mechanisms involved in the Kv7 channel-opening action of retigabine, the activity of retigabine in preclinical in vitro and in vivo studies predictive of anticonvulsant activities, and the clinical status of development for this drug as an add-on treatment for pharmacoresistant epilepsy. Particular efforts are devoted to highlighting the potential advantages and disadvantages of retigabine when compared with currently available compounds, in order to provide a comprehensive assessment of its role in therapy for treatment-resistant epilepsies.

Keywords: epilepsy, retigabine, potassium channels, antiepileptic drugs, Kv7 channels

Erratum for this paper has been published

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Erratum

Barrese V, Miceli F, Soldovieri MV, Ambrosino P, Iannotti FA, Cilio MR, Taglialatela M

Clinical Pharmacology: Advances and Applications 2012, 4:23-24

Published Date: 26 March 2012

Readers of this article also read:

Facial transplantation: a review of ethics, progress, and future targets

Edwards JA, Mathes DW

Transplant Research and Risk Management 2011, 3:113-125

Published Date: 5 September 2011

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder

Xianchen Liu, Yi Chen, Douglas E Faries, et al

ClinicoEconomics and Outcomes Research 2011, 3:63-72

Published Date: 15 March 2011

Chronomodulated press-coated pulsatile therapeutic system for aceclofenac: optimization of factors influencing drug release and lag time

Sumit Patil, Swati Pund, Amita Joshi, et al

ChronoPhysiology and Therapy 2011, 1:1-10

Published Date: 21 February 2011

Neurotransmitter testing of the urine: a comprehensive analysis

Marty Hinz, Alvin Stein, George Trachte, et al

Research and Reports in Urology 2010, 2:177-183

Published Date: 7 October 2010

The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?

Rakesh K Sharma, Hanumanth K Reddy, Rohit K Sharma, et al

Clinical Pharmacology: Advances and Applications 2010, 2:155-162

Published Date: 6 September 2010

Bone resorption in incompletely impacted mandibular third molars and acute pericoronitis

Minoru Yamaoka, Yusuke Ono, Masahiro Takahashi, Ryosuke Doto, et al.

Clinical, Cosmetic and Investigational Dentistry 2009, 1:7-12

Published Date: 14 April 2009